Ministry Of Defence

Ministry Of Defence, operating in the federal market as Defence Science and Technology Laboratory (DSTL), is a United Kingdom government research entity that delivers advanced biotechnology, medical countermeasures, and defense-related research and development to U.S. federal agencies as a prime contractor exclusively — the vendor holds no subcontract footprint across its 97 recorded federal awards. DSTL operates outside conventional small-business set-aside categories; all recent prime work is full-and-open, non-set-aside contracting, reflecting its foreign-government ownership and specialized scientific capabilities that position it as a sole-source or limited-competition performer for CBRN (chemical, biological, radiological, and nuclear) threat research.

DSTL's federal customer concentration is heavily weighted toward defense and biodefense agencies, though the dollar profile diverges sharply from award count. The Defense Threat Reduction Agency (DTRA) dominates by volume (59 awards, $141.4 million combined potential value), but the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response and the National Institute of Allergy and Infectious Diseases together anchor $390.4 million in potential value across just six awards, driven by a single $146.3 million seven-year indefinite delivery contract for pre-clinical models of infectious diseases issued by NIAID in July 2024. That NIAID vehicle carries four task areas — small animal models, non-human primate models, animal replacement and non-traditional models, and specialized reagent generation — and represents the largest single vehicle in DSTL's federal footprint. DTRA's two largest standing IDVs (HDTRA112D0003 and DTRA0103D0001) have generated 40 task orders worth $80.5 million combined. Department of the Army Medical Command and Army Contracting Command Aberdeen Proving Ground round out the active customer set with smaller, applied research awards totaling $10.7 million.

Recent concrete work includes a $1.75 million Other Transaction Agreement with the U.S. Army Research Development and Engineering Command (award date March 18, 2026, through March 17, 2029) for development of a modular artificial intelligence and machine learning-enabled encapsulation decision support minimum viable product; an $8.4 million DTRA definitive contract (June 10, 2024, through December 9, 2029) for novel antibody-antibiotic conjugate platform research to address melioidosis and plague treatment; a $6.4 million DTRA definitive contract (September 28, 2022, through September 27, 2027) for non-ionic surfactant vesicles as drug delivery systems for antimicrobials; and a $870,269 DTRA fundamental research contract (September 30, 2022, through September 29, 2025) on deep learning development and evaluation frameworks. DSTL's capability portfolio is concentrated in NAICS 541712 (Research and Development in Biotechnology) and PSC R&D-Defense Other applied research, with secondary depth in life-sciences R&D and biological product manufacturing. Activity has been sparse in the past five years — one or two awards annually from 2020 through 2022, then two in 2024 and one in 2026 — though the dollar value per award has grown substantially. Only one award ($6.4 million) reaches ultimate completion in the next twenty-four months, indicating minimal recompete pressure through mid-2028. Place of performance for all work is Great Britain, United Kingdom.